1. Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme. Issue 7 (July 2021) Authors: Chan, O.S.H.; Lee, V.H.F.; Nyaw, S.F.; Kam, M.T.Y.; Lee, K.W.C.; Lam, K.C. Journal: Clinical oncology Issue: Volume 33:Issue 7(2021) Page Start: e305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib. (February 2017) Authors: Hochmair, M.; Cappuzzo, F.; Tsai, C.M.; Schuler, M.; Lam, K.C.; Stehle, G.; Cseh, A.; Lorence, R.M.; Linden, S.; Carrière, P.; Soo, R. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗